Despite setbacks, Pfizer Inc. believes its oral GLP-1 agonist danuglipron remains in a competitive position versus rivals. Investors are hyper-focused on the development of danuglipron for obesity, even though it remains relatively early days, because of the multibillion-dollar market opportunity and the fast-changing competitive dynamics.
Key Takeaways
- Pfizer reported solid second quarter sales and earnings growth, given declining sales of the COVID-19 vaccine Comirnaty, offset by legacy Seagen products.
During Pfizer’s second quarter sales and earnings call on 30 July, CEO Albert Bourla said the company hopes to move...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?